Update on biomarkers in psoriatic arthritis

Current Rheumatology Reports

Volumn 12, Issue 4, 2010, Pages 288-294

  Chandran, Vinod ^a   Gladman, Dafna D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Biomarkers; Gene; Joint damage; Osteoclast precursors; Psoriasis; Psoriatic arthritis; Screening

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CYTOKINE; ETANERCEPT; HLA C ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 4; METHOTREXATE; PLACEBO; TOCILIZUMAB; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA; C REACTIVE PROTEIN; STROMELYSIN;

CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; JOINT INJURY; LIVER TOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RNA ANALYSIS; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; METABOLISM; OSTEOCLAST;

ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; MATRIX METALLOPROTEINASE 3; OSTEOCLASTS;

EID: 77955982721     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0107-0     Document Type: Review

References (52)

1. Biomarkers Definitions Working Group 2001 Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 89 95 10.1067/mcp.2001.113989
2. Wright V, Moll JMH: Psoriatic arthritis. In Seronegative Polyarthritis. Amsterdam, The Netherlands: North Holland Publishing Co.; 1976:169-223.
3. W Taylor D Gladman P Helliwell CASPAR Study Group, et al. 2006 Classification criteria for psoriatic arthritis: development of new criteria from a large international study Arthritis Rheum 54 2665 2673 10.1002/art.21972 16871531
4. O Fitzgerald R Winchester 2009 Psoriatic arthritis: from pathogenesis to therapy Arthritis Res Ther 11 214 10.1186/ar2580 19232079
5. DD Gladman C Antoni P Mease, et al. 2005 Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 Suppl 2 ii14 ii17 10.1136/ard.2004.032482 15708927
6. DD Gladman 1994 Natural history of psoriatic arthritis Baillieres Clin Rheumatol 8 379 394 10.1016/S0950-3579(94)80024-3 1:STN:280:DyaK2czls12isQ%3D%3D 8076393
7. J Fransen C Antoni PJ Mease, et al. 2006 Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors Ann Rheum Dis 65 1373 1378 10.1136/ard.2006.051706 1:CAS:528:DC%2BD28Xht1egsLfO 16644783
8. PY Ho A Barton J Worthington, et al. 2008 Investigating the role of the HLA-Cw 06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis Ann Rheum Dis 67 677 682 10.1136/ard.2007.071399 1:STN:280:DC%2BD1c3ksVaktg%3D%3D 17728335
9. M Cargill SJ Schrodi M Chang, et al. 2007 A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes Am J Hum Genet 80 273 290 10.1086/511051 1:CAS:528:DC%2BD2sXhtlOju70%3D 17236132
10. RP Nair KC Duffin C Helms Collaborative Association Study of Psoriasis, et al. 2009 Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways Nat Genet 41 199 204 10.1038/ng.311 1:CAS:528: DC%2BD1MXhtVWmtb8%3D 19169254 This article reports on the first large-scale genome-wide study to include PsA patients. Genetic associations with psoriasis, PsA, and differences between psoriasis and PsA are reported
11. P Rahman RD Inman WP Maksymowych, et al. 2009 Association of interleukin 23 receptor variants with psoriatic arthritis J Rheumatol 36 137 140 1:CAS:528:DC%2BD1MXit1Cmtrw%3D 19040306
12. C Filer P Ho RL Smith, et al. 2008 Investigation of association of the IL12B and IL23R genes with psoriatic arthritis Arthritis Rheum 58 3705 3709 10.1002/art.24128 1:CAS:528:DC%2BD1MXmt1ymsA%3D%3D 19035472
13. U Hüffmeier J Lascorz B Böhm, et al. 2009 Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis J Invest Dermatol 129 355 358 10.1038/jid.2008.233 18800148
14. Y Liu C Helms W Liao, et al. 2008 A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci PLoS Genet 4 e1000041 10.1371/journal.pgen.1000041 18369459
15. TG Day AV Ramanan A Hinks, et al. 2008 Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis Arthritis Rheum 58 2142 2146 10.1002/art.23604 1:CAS:528:DC%2BD1cXpt1Wrsrw%3D 18576390
16. J Soto-Sánchez J Santos-Juanes P Coto-Segura, et al. 2010 Genetic variation at the CCR5/CCR2 gene cluster and risk of psoriasis and psoriatic arthritis Cytokine 50 114 116 10.1016/j.cyto.2010.01.006 20153665
17. DD Gladman VT Farewell 1995 The role of HLA antigens as indicators of progression in psoriatic arthritis. Multivariate relative risk model Arthritis Rheum 38 845 850 10.1002/art.1780380619 1:STN:280:DyaK2M3pvVSksA%3D%3D 7779129
18. J Balding D Kane W Livingstone, et al. 2003 Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity Arthritis Rheum 48 1408 1413 10.1002/art.10935 1:CAS:528:DC%2BD3sXkt1akt78%3D 12746914
19. P Rahman T Snelgrove L Peddle, et al. 2008 A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis Arthritis Rheum 58 2207 2208 10.1002/art.23558 18576348
20. J Lascorz U Hüffmeier H Schulze-Koops, et al. 2006 Lack of genetic association of the interleukin-4 receptor single-nucleotide polymorphisms I50V and Q551R with erosive disease in psoriatic arthritis Arthritis Rheum 54 4023 4024 10.1002/art.22278 1:CAS:528:DC%2BD2sXktlaksQ%3D%3D 17133536
21. M Seitz U Wirthmüller B Möller PM Villiger 2007 The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients Rheumatology (Oxford) 46 93 96 10.1093/rheumatology/kel175 1:CAS:528: DC%2BD28XhtlChtbbJ
22. Chandran V, Siannis F, Rahman P, et al.: Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol 2010 (in press).
23. FM Batliwalla W Li CT Ritchlin, et al. 2005 Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis Mol Med 11 21 29 10.2119/2006-00003.Gulko 1:CAS:528: DC%2BD28XlvVelsrw%3D 16622521
24. AK Stoeckman EC Baechler WA Ortmann, et al. 2006 A distinct inflammatory gene expression profile in patients with psoriatic arthritis Genes Immun 7 583 591 10.1038/sj.gene.6364334 1:CAS:528:DC%2BD28XhtFWns7nL 16971957
25. D Grcevic Z Jajic N Kovacic, et al. 2010 Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness J Rheumatol 37 246 256 10.3899/jrheum.090167 20008919 This gene expression study on patients with PsA, ankylosing spondylitis, RA, and osteoarthritis and healthy controls reported the similarities and differences of peripheral blood expression profiles of bone-regulatory factors as markers of the form of arthritis, disease activity, and therapeutic responsiveness
26. DD Gladman R Pollock C Virtanen, et al. 2009 Microarray analyses of peripheral blood cells identifies gene expression profile that differentiates psoriatic arthritis (PsA) from psoriasis and controls Arthritis Rheum 60 S537
27. PM Ridker DA Morrow 2003 C-reactive protein, inflammation, and coronary risk Cardiol Clin 21 315 325 10.1016/S0733-8651(03)00079-1 14621448
28. LS Tam B Tomlinson TT Chu, et al. 2008 Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation Rheumatology (Oxford) 47 718 723 10.1093/rheumatology/ken090
29. B Strober C Teller P Yamauchi, et al. 2008 Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis Br J Dermatol 159 322 330 10.1111/j.1365-2133.2008.08628.x 1:CAS:528:DC%2BD1cXhtVCqs7nI 18503600 The results from this randomized trial demonstrate that hsCRP elevation in patients with moderate to severe psoriasis is attributable to the presence of PsA as well as the degree of skin involvement
30. GM Alenius C Eriksson S Rantapää Dahlqvist 2009 Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol 27 120 123 19327240
31. T Saxne D Heinegard 1992 Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood Br J Rheumatol 31 583 591 10.1093/rheumatology/31.9.583 1:STN:280: DyaK38vgsVylsQ%3D%3D 1381980 Published erratum appears in Br J Rheumatol 1993, 32:247
32. M Skoumal G Haberhauer A Fink, et al. 2008 Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? Clin Exp Rheumatol 26 1087 1090 1:STN:280:DC%2BD1M7jsFCrtQ%3D%3D 19210875
33. Chandran V, Cook RJ, Edwin J, et al.: Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 2010 (in press).
34. F Van den Bosch B Manger P Goupille, et al. 2010 Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions Ann Rheum Dis 69 394 399 10.1136/ard.2009.111856 19815494 This large, open-label, uncontrolled study in PsA demonstrated that elevated CRP is a predictor for achieving an ACR 50 response with adalimumab
35. J Gratacós E Casado J Real JC Torre-Alonso 2007 Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate Ann Rheum Dis 66 493 497 10.1136/ard.2006.060079 17179176
36. V Chandran H Shen R Pollock, et al. 2009 Soluble biomarkers predict response to anti-tumour necrosis factor (TNF) therapy in psoriatic arthritis Arthritis Rheum 60 S666
37. LE Kristensen A Gülfe T Saxne P Geborek 2008 Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register Ann Rheum Dis 67 364 369 10.1136/ard.2007.073544 1:CAS:528:DC%2BD1cXjs1ejs7s%3D 17644547 Results from a large biologics registry indicated that high CRP levels and concomitant MTX treatment are associated with longer treatment continuation of anti-TNF therapy in patients with PsA. The duration of treatment is a composite measure of drug effectiveness and encompasses factors such as adverse drug reactions, side effects, poor adherence, and loss of efficacy
38. CT Ritchlin SA Haas-Smith P Li, et al. 2003 Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J Clin Invest 111 821 831 1:CAS:528:DC%2BD3sXitlOjsbc%3D 12639988
39. AP Anandarajah EM Schwarz S Totterman, et al. 2008 The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis Ann Rheum Dis 67 296 301 10.1136/ard.2007. 076091 1:CAS:528:DC%2BD1cXjs1aqu7w%3D 17967829 This study shows that OCP frequency decreases on treatment with etanercept but does not correlate with changes in bone edema and clinical parameters
40. YG Chiu T Shao C Feng, et al. 2010 CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis Arthritis Res Ther 12 R14 10.1186/ar2915 20102624 This study found an elevated frequency of circulating CD14+CD16+ cells in PsA patients compared with controls. The level of CD16 expression correlated with the bone resorption activity; thus, CD16 is a marker for OCPs. This study takes us one step closer to using OCP frequency as a biomarker for structural joint damage in clinical practice
41. GE Pamuk O Nuri Pamuk H Orüm, et al. 2009 Elevated platelet-monocyte complexes in patients with psoriatic arthritis Platelets 20 493 497 10.3109/09537100903165174 1:CAS:528:DC%2BD1MXhs1SktrfN 19852688
42. J Sarma CA Laan S Alam, et al. 2002 Increased platelet binding to circulating monocytes in acute coronary syndromes Circulation 105 2166 2171 10.1161/01.CIR.0000015700.27754.6F 11994250
43. E Kruithof D Baeten L De Rycke, et al. 2005 Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis Arthritis Res Ther 7 R569 R580 10.1186/ar1698 1:CAS:528:DC%2BD2MXivVWqurw%3D 15899044
44. AW van Kuijk DM Gerlag K Vos, et al. 2009 A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue Ann Rheum Dis 68 1303 1309 10.1136/ard.2008.091389 18647851 This study identified synovial biomarkers of response to treatment with adalimumab. The study design and results provide a framework for short proof-of-concept studies with newer biologic agents
45. RJ Lories I Derese FP Luyten K de Vlam 2008 Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment Clin Exp Rheumatol 26 96 102 1:STN:280: DC%2BD1c7ntVegsQ%3D%3D 18328153
46. YM Tan M Ostergaard A Doyle, et al. 2009 MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage Arthritis Res Ther 11 R2 10.1186/ar2586 19126234
47. H Marzo-Ortega D McGonagle LA Rhodes, et al. 2007 Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis Ann Rheum Dis 66 778 781 10.1136/ard.2006.063818 1:CAS:528:DC%2BD2sXntlOmsr8%3D 17185324
48. AP Anandarajah P Ory D Salonen, et al. 2010 Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging Ann Rheum Dis 69 206 209 10.1136/ard.2008.100149 1:CAS:528:DC%2BC3cXhtFOlsL8%3D 19204015
49. Weckbach S, Schewe S, Michaely HJ, et al.: Whole-body MR imaging in psoriatic arthritis: additional value for therapeutic decision making. Eur J Radiol 2009 Jul 23 (Epub ahead of print).
50. N Raza A Hameed MK Ali 2008 Detection of subclinical joint involvement in psoriasis with bone scintigraphy and its response to oral methotrexate Clin Exp Dermatol 33 70 73 1:STN:280:DC%2BD1c%2FgvF2ltw%3D%3D 18076689
51. CT Ritchlin AA Qureshi K de Vlam, et al. 2010 Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008 J Rheumatol 37 462 467 10.3899/jrheum.090957 20147482 This review describes the framework for a planned international initiative to identify biomarkers for structural joint damage in PsA
52. WP Maksymowych R Landewé PP Tak, et al. 2009 Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria J Rheumatol 36 1785 1791 10.3899/jrheum.090346 19671813